21.06.2013 - Swiss vaccine developer AmVac AG has bagged EU funding in two FP7 projects worth €5.5m and €6m.
The projects aims to develop innovative vaccines against flu and leishmaniasis including Phase I safety testing. The first one of the 5-year projects is aimed at developing a universal flu vaccine that can be used over several years. While traditional flu vaccines target highly variable antigens on the virus' surface and must be adapted and newly produced each year, the new vaccine will be based on antigens that are well conserved across the strains and largely stable over time. AmVac will be involved in vaccine design and contributes its MALP adjuvant to optimize efficacy. Moreover, AmVac will support the establishment of GMP (Good Manufacturing Practice) vaccine manufacturing.
The second project targets leishmaniasis, an infectious disease transmitted by certain species of sand fly. It is found in parts of the tropics, subtropics and southern Europe. Currently, there is no vaccine available. A first-in-class vaccine could not only protect the local population but also tourists travelling to endemic regions. AmVac will support pre-clinical testing and manufacturing according to GMP standards.
Funds provided under the FP7 programme only require a 25% contribution in kind by small and medium-size companies such as AmVac. 'It is an excellent opportunity to leverage our investments and create significant potential for patients and investors - even more so, as both projects are expected to complete first clinical trials within the funding periods,' Melinda Karpati, CEO of AmVac comments.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.